Isthmus Partners LLC Grows Stock Position in DexCom, Inc. $DXCM

Isthmus Partners LLC boosted its position in DexCom, Inc. (NASDAQ:DXCM) by 5.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 176,453 shares of the medical device company’s stock after buying an additional 8,667 shares during the quarter. Isthmus Partners LLC’s holdings in DexCom were worth $11,711,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Gradient Investments LLC increased its position in DexCom by 13.8% in the fourth quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company’s stock worth $22,035,000 after buying an additional 40,343 shares during the last quarter. Nordea Investment Management AB grew its position in shares of DexCom by 118.6% in the fourth quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company’s stock valued at $16,988,000 after purchasing an additional 137,986 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of DexCom by 11.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 212,045 shares of the medical device company’s stock valued at $14,269,000 after purchasing an additional 21,352 shares in the last quarter. NEOS Investment Management LLC grew its position in shares of DexCom by 58.7% in the third quarter. NEOS Investment Management LLC now owns 175,982 shares of the medical device company’s stock valued at $11,842,000 after purchasing an additional 65,066 shares in the last quarter. Finally, Peterson Wealth Services grew its position in shares of DexCom by 423.6% in the third quarter. Peterson Wealth Services now owns 28,937 shares of the medical device company’s stock valued at $1,947,000 after purchasing an additional 23,410 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Price Performance

DexCom stock opened at $61.63 on Friday. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The business has a 50-day simple moving average of $63.46 and a 200 day simple moving average of $65.89. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The stock has a market cap of $23.78 billion, a price-to-earnings ratio of 26.34, a PEG ratio of 1.00 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the previous year, the business earned $0.32 earnings per share. The firm’s revenue was up 15.0% on a year-over-year basis. On average, research analysts forecast that DexCom, Inc. will post 2.56 earnings per share for the current fiscal year.

More DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom outlined a 2030 growth plan calling for at least 10% annual revenue growth through 2030, along with margin targets that suggest improving profitability over time. Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
• Positive Sentiment: The company authorized a new $1 billion share buyback, which can support the stock by signaling confidence in future cash flow and returning capital to shareholders. Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
• Positive Sentiment: Management also highlighted next-generation products, including the G8 glucose sensor and dual-analyte sensing, which could expand DexCom’s competitive position and addressable market. Dexcom to add 2 board directors with activist investor Elliott
• Positive Sentiment: DexCom and Elliott Investment Management agreed to add two independent directors to the board and revise governance, a move that may improve oversight and strategic execution. Dexcom to appoint two directors, revamp board committee with Elliott
• Neutral Sentiment: Wall Street sentiment remains constructive overall, with a “Moderate Buy” consensus and an average price target above recent trading levels, though there are still some hold and underweight ratings in the mix. Are Wall Street analysts bullish on DexCom’s stock?
• Negative Sentiment: Director Bridgette Heller sold 1,012 shares, but the transaction was small and was made under a pre-arranged trading plan, so it is less likely to be a major negative signal. Bridgette Heller Sells 1,012 Shares of DexCom (NASDAQ:DXCM) Stock

Insider Activity

In related news, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the completion of the transaction, the executive vice president directly owned 111,204 shares in the company, valued at $7,010,300.16. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. The trade was a 3.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 4,412 shares of company stock valued at $278,143. 0.28% of the stock is owned by company insiders.

Analysts Set New Price Targets

DXCM has been the subject of several recent research reports. Canaccord Genuity Group set a $100.00 price target on DexCom and gave the company a “buy” rating in a research report on Friday, May 1st. Truist Financial reiterated a “buy” rating and issued a $80.00 price target (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Weiss Ratings upgraded DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, March 4th. Evercore upgraded DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price target for the company in a research report on Tuesday, March 24th. Finally, Piper Sandler reiterated an “overweight” rating on shares of DexCom in a research report on Thursday, February 5th. Three analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $83.22.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.